Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700521 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL12152296 | 0.85 | ALDH1A1 (0.53) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL37830 | 0.83 | MAPT (0.63) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL4295085 | 0.83 | MAPT (0.63) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL29928397 | 0.83 | MAPT (0.63) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL17131448 | 0.82 | DGAT1 (0.51) | ALDH1A1MAPTKDM4EPOLBPKM | |
| SCHEMBL31558613 | 0.82 | FOLH1 (0.47) | ALDH1A1MAPTKDM4EPOLBFOLH1 | |
| SCHEMBL9755054 | 0.81 | MAPT (0.65) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL30763639 | 0.81 | FOLH1 (0.47) | ALDH1A1MAPTKDM4EPOLBHCAR3 | |
| SCHEMBL17875231 | 0.81 | MAPT (0.56) | ALDH1A1MAPTKDM4EPOLBHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | ALDH1A1 1951/4885MAPT 728/4885KDM4E 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.